Medicrea reported 3Q19 revenue of €8.2million (USD $9.2 million), +12.3% vs. 3Q18.
- Growth was driven by strength in key markets like the U.S. (+17.8%) and Belgium (+15%)
- In 3Q19, 500 surgeries were performed with Medicrea patient-specific implants, representing a 57% increase overall vs. the prior year (+77% in the U.S.)
- The company anticipates reaching the 5000th cumulative implant of their patient-specific rods by the end of 2019
- ORTHOWORLD projects Medicrea full year 2019 revenue of $37.7 million, +4.3% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $7.7 | $6.8 | $0.9 | 13% |
| Orthobiologics | $1.5 | $1.4 | $0.1 | 9% |
| Total | $9.2 | $8.2 | $1.0 | 12.3% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $22.7 | $22.6 | $0.1 | 0.6% |
| Orthobiologics | $4.6 | $4.6 | ($0.0) | (0.6%) |
| Total | $27.3 | $27.2 | $0.1 | 0.4% |
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $5.2 | $4.4 | $0.8 | 17.8% |
| Ex-US | $4.0 | $3.8 | $0.2 | 5.9% |
| Total | $9.2 | $8.2 | $1.0 | 12.3% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Medicrea reported 3Q19 revenue of €8.2million (USD $9.2 million), +12.3% vs. 3Q18.
Growth was driven by strength in key markets like the U.S. (+17.8%) and Belgium (+15%)
In 3Q19, 500 surgeries were performed with Medicrea patient-specific implants, representing a 57% increase overall vs. the prior year (+77% in the U.S.)
The...
Medicrea reported 3Q19 revenue of €8.2million (USD $9.2 million), +12.3% vs. 3Q18.
- Growth was driven by strength in key markets like the U.S. (+17.8%) and Belgium (+15%)
- In 3Q19, 500 surgeries were performed with Medicrea patient-specific implants, representing a 57% increase overall vs. the prior year (+77% in the U.S.)
- The company anticipates reaching the 5000th cumulative implant of their patient-specific rods by the end of 2019
- ORTHOWORLD projects Medicrea full year 2019 revenue of $37.7 million, +4.3% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $7.7 | $6.8 | $0.9 | 13% |
| Orthobiologics | $1.5 | $1.4 | $0.1 | 9% |
| Total | $9.2 | $8.2 | $1.0 | 12.3% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $22.7 | $22.6 | $0.1 | 0.6% |
| Orthobiologics | $4.6 | $4.6 | ($0.0) | (0.6%) |
| Total | $27.3 | $27.2 | $0.1 | 0.4% |
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $5.2 | $4.4 | $0.8 | 17.8% |
| Ex-US | $4.0 | $3.8 | $0.2 | 5.9% |
| Total | $9.2 | $8.2 | $1.0 | 12.3% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.





